Goldman Sachs
LRMR icon

Goldman Sachs’s Larimar Therapeutics LRMR Stock Holding History

Goldman Sachs’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Hold
90,000
– – ﹤0.01% 6045
2026
Q1 		$405K Buy
+90,000
New +$360K ﹤0.01% 5732

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Goldman Sachs's LRMR Position: Q2 2026 in Review

Goldman Sachs increased its Larimar Therapeutics (LRMR) stake by 12% in Q2 2026, buying an estimated $760K and bringing the position to 1,752,910 shares worth $5.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

Goldman Sachs first reported a position in LRMR in Q3 2014 and has held it in 38 quarters since. The position peaked at $31.4M in Q2 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Goldman Sachs held 1,752,910 shares of Larimar Therapeutics worth $5.35M as of Q2 2026.
  • Goldman Sachs bought 191,325 Larimar Therapeutics shares in Q2 2026, an estimated $760K.
  • Larimar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3827 holding.
  • Goldman Sachs first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 38 quarters since.
  • Goldman Sachs's Larimar Therapeutics position peaked at $31.4M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.